Aktis Oncology, Inc. employees and revenue per employee

AKTS · Biotechnology · $969M market cap

Aktis Oncology, Inc. had 200,000 employees at the end of fiscal Dec 2025. Revenue for the year was $6.5M, or $32 per employee.

Employees

200,000

Revenue

$6.5M

Revenue / employee

$32

Peer median $459K

Rank in industry

108 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

Only one fiscal year on file so far, so there is no trend to draw yet.

Employees, last six fiscal years
200,000'25
Revenue per employee, last six fiscal years
$32'25

Aktis Oncology, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

CompanyEmployeesRevenueRevenue / employeeShape
CBIO
Crescent Biopharma, Inc.
44$10.8M$246K—
JANX
Janux Therapeutics, Inc.
109$10.0M$92KHiring into decline
PRAX
Praxis Precision Medicines, Inc.
116$8.6M$74KEfficient growth
PGEN
Precigen, Inc.
160$9.7M$61KEfficient growth
ZBIO
Zenas BioPharma, Inc.
167$10.0M$60KEfficient growth
IMNM
Immunome, Inc.
177$6.9M$39KHiring into decline
CGON
CG Oncology Inc.
142$4.0M$28KEfficient growth
CRNX
Crinetics Pharmaceuticals, Inc.
594$7.7M$13KEfficient growth
AKTS
Aktis Oncology, Inc.
200,000$6.5M$32—
Every Healthcare company

Questions about Aktis Oncology, Inc.

How many employees does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. reported 200,000 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 30, 2026.
What is Aktis Oncology, Inc.'s revenue per employee?
Aktis Oncology, Inc. brought in $6.5M of revenue in fiscal Dec 2025, which is $32 per employee. That ranks 108 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?
Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

Compare AKTS with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Source: employee counts and revenue as stated in Aktis Oncology, Inc.'s annual reports (Form 10-K), latest filed March 30, 2026. This is data, not a recommendation to buy or sell AKTS.